ISIS Licenses Antisense Programme to BMS for Cardiovascular collaboration
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 84 (Table of Contents)
Published: 7 Jun-2007
DOI: 10.3833/pdr.v2007.i84.334 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
ISIS Pharmaceuticals and Bristol-Meyers Squibb entered into license agreement to discover, develop and commercialize antisense drugs targeting proprotein convertase subtilisin kexin 9 (PCSK9) for preventing and treating cardiovascular disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS